Release Date: 2023-09-14

Effects of Sulphanure Drugs on Diabetics

Ercan Karabulut (Author)

Release Date: 2023-09-14

Sulfonylurea drugs are widely used in the treatment of type 2 diabetes to lower blood glucose levels by stimulating insulin secretion from pancreatic beta cells. They act by binding to ATP-sensitive potassium channels on these cells, causing depolarization and subsequent insulin release. Despite their effectiveness in improving glycemic control, sulfonylureas can lead to several side [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Perspective on Diabetes Mellitus in Clinical Sciences
First Page125
Last Page132
DOIhttps://doi.org/10.69860/nobel.9786053359111.11
ISBN978-605-335-911-1 (PDF)
LanguageENG
Page Count8
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Sulfonylurea drugs are widely used in the treatment of type 2 diabetes to lower blood glucose levels by stimulating insulin secretion from pancreatic beta cells. They act by binding to ATP-sensitive potassium channels on these cells, causing depolarization and subsequent insulin release. Despite their effectiveness in improving glycemic control, sulfonylureas can lead to several side effects. Hypoglycemia is a significant concern, especially in elderly patients or those with renal impairment, due to their long duration of action and potential for cumulative effects. Additionally, sulfonylureas can cause weight gain, as they may increase appetite and promote fat storage. Long-term use has been associated with beta cell exhaustion and reduced insulin secretion, potentially leading to secondary failure of treatment over time. Moreover, some individuals may experience allergic reactions or gastrointestinal disturbances. Despite these drawbacks, sulfonylureas remain a valuable option in diabetes management, particularly when cost, accessibility, and patient preference are considered alongside their efficacy and side effect profile.

Ercan Karabulut (Author)
Associate Professor, Ankara Yildirim Beyazit University
https://orcid.org/0000-0001-6733-2497

  • Lachance CH. Practical Aspects of Monogenic Diabetes: A Clinical Point of View. Can J Diabetes. 2016 Oct;40(5):368–75.

  • Zimmerman BR. SULFONYLUREAS. Endocrinol Metab Clin North Am. 1997 Sep;26(3):511–22.

  • Scheen AJ. Sulphonylureas in the management of type 2 diabetes: To be or not to be? Diabetes Epidemiology and Management. 2021 Jan;1:100002.

  • Melander A, Bitzén PO, Faber O, Groop L. Sulphonylurea Antidiabetic Drugs: An Update of Their Clinical Pharmacology and Rational Therapeutic Use. Vol. 37, Drugs. 1989.

  • Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open. 2014;2(3).

  • Drugs MR, 2004 undefi ned. The role of sulphonylureas in the management of type 2 diabetes mellitus. Springer [Internet]. [cited 2023 Jan 27]; Available from: https://idp.springer.com/authorize/casa?redirect_uri=https://link.springer.com/article/10.2165/00003495-200464120-00006&casa_token=qXHnemlqsoYAAAAA:Ou 8PmoyBUdODDzyOa38lFBMgptoII-QuQnhGPdsaNK_duRB0NOIessrLB0xElczdcYNYCsazIgd_-8A

  • Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004;64(12):1339–58.

  • 9.mellitus. Diagnosis and treatment. An interpretation]. Ugeskr Laeger. 1990;152(1).

  • Kaliszan R, Siluk D, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia. 2002;45:1034–7.

  • Qi R, Ozaki Y, Satoh K, Kurota K, Asazuma N, Yatomi Y, et al. Sulphonylurea agents inhibit platelet aggregationand [Ca2+]i elevation induced by arachidonic acid. Biochem Pharmacol. 1995 Jun 16;49(12):1735–9.

  • Ferner RE, Chaplin S. The Relationship Between the Pharmacokinetics and Pharmacodynamic Effects of Oral Hypoglycaemic Drugs. Vol. 12, Clinical Pharmacokinetics. 1987.

  • Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Vol. 14, Diabetes Research and Clinical Practice. 1991.

  • Groop L, Groop P, Stenman S, … CSD, 1987 undefi ned. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Am Diabetes Assoc [Internet]. [cited 2023 Feb 17]; Available from: https://diabetesjournals.org/care/article-abstract/ 10/6/671/2414

  • Groop L, Luzi L, Melander A, Groop P, Diabetes KR, 1987 undefi ned. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Am Diabetes Assoc [Internet]. [cited 2023 Feb 17]; Available from: https://diabetesjournals.org/diabetes/articleabstract/ 36/11/1320/6699

  • Sola D, Rossi L, Schianca GPC, Maffi oli P, Bigliocca M, Mella R, et al. State of the art paper Sulfonylureas and their use in clinical practice. Archives of Medical Science. 2015;4:840–8.

  • Bell DSH. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ [Internet]. 2006 Jan 17 [cited 2023 Feb 23];174(2):185–6. Available from: https://www.cmaj.ca/content/174/2/185

  • Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: Scientifi c review. Vol. 287, JAMA. 2002.

  • van Dalem J, Brouwers MCGJ, Stehouwer CDA, Krings A, Leufkens HGM, Driessen JHM, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: Population based cohort study. BMJ (Online). 2016;354.

  • Jackuliak P, Kužma M, Payer J. Effect of Antidiabetic Treatment on Bone. [cited 2023 Feb 27]; Available from: www.biomed.cas.cz/physiolresPhysiol.Res.68

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!